Physician profile
Angela S Moore
NPI 1184864076
$8,321.60
in general payments reported to CMS, 2019-2025
50 companies · $204 in 2025
The $204 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,559 · 2020: $1,861 · 2021: $2,474 · 2022: $1,622 · 2023: $509 · 2024: $93.10 · 2025: $204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $806.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $806.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,002.14 | 2019-2024 | |
| Novo Nordisk INC | $991.64 | 2019-2023 | Rybelsus, Ozempic |
| Amgen INC. | $826.73 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $679.01 | 2019-2024 | Airsupra |
| Lilly USA, LLC | $623.73 | 2019-2025 | Mounjaro, Emgality, Jardiance |
| Amarin Pharma, INC. | $547.38 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $314.84 | 2019-2022 | |
| Biohaven Pharmaceuticals, INC. | $255.82 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $239.64 | 2019-2023 | Xifaxan, Trulance |
| Horizon Therapeutics Plc | $218.35 | 2019-2022 | |
| Supernus Pharmaceuticals, INC. | $210.14 | 2019-2021 | |
| Glaxosmithkline, LLC. | $170.74 | 2019-2022 | |
| Teva Pharmaceuticals USA, INC. | $165.69 | 2019-2021 | |
| Pfizer INC. | $160.92 | 2020-2025 | |
| Currax Pharmaceuticals LLC | $152.56 | 2021-2023 | Contrave, Nexlizet, Nexletol |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Angela Moore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.